All Stories

  1. Pharmacokinetic evaluation of intranasal ropinirole delivery using hybrid polymer/surfactant/βCD systems in C57BL/6J mice
  2. Ex Vivo Characterization and In Vivo Nasal Delivery of Ropinirole-Loaded PEO-b-PCL/Tween 80/β-Cyclodextrin Systems in C57BL/6J Mice
  3. Cannabinoids and drug–drug pharmacokinetic interactions: Deciphering the risks
  4. Therapeutic Potential of Quercetin, Silibinin, and Crocetin in a High-Fat Diet-Induced Mouse Model of MASLD: The Role of CD36 and PLIN3
  5. Advanced P407/Tw80/βCD based Nasal Powders of Ropinirole Hydrochloride for Nose-to-Brain Delivery in Parkinson’s Disease: Preparation and Comprehensive In Vitro and Ex Vivo Evaluation
  6. Cyclodextrin-Based Quercetin Powders for Potential Nose-to-Brain Transport: Formulation and In Vitro Assessment
  7. pH-Responsive Hydrogels: Recent Advances in Pharmaceutical Applications
  8. Spectroscopic Characterization Using 1H and 13C Nuclear Magnetic Resonance and Computational Analysis of the Complex of Donepezil with 2,6-Methyl-β-Cyclodextrin and Hydroxy Propyl Methyl Cellulose
  9. The Effect of Quercetin on Non-Alcoholic Fatty Liver Disease (NAFLD) and the Role of Beclin1, P62, and LC3: An Experimental Study
  10. Quercetin’s Potential in MASLD: Investigating the Role of Autophagy and Key Molecular Pathways in Liver Steatosis and Inflammation
  11. Pharmacokinetic Study of Fingolimod Nasal Films Administered via Nose-to-Brain Route in C57BL/6 J Mice as Potential Treatment for Multiple Sclerosis
  12. Unveiling the Performance of Co-Assembled Hybrid Nanocarriers: Moving towards the Formation of a Multifunctional Lipid/Random Copolymer Nanoplatform
  13. The Effect of Donepezil Hydrochloride in the Twitcher Mouse Model of Krabbe Disease
  14. Fabricating hybrid DSPC:DOPC:P(OEGMA-co-LMA) structures: Self-assembly as the milestone of their performance
  15. The Complex Mechanisms and the Potential Effects of Statins on Vascular Calcification: A Narrative Review
  16. Fabricating Polymer/Surfactant/Cyclodextrin Hybrid Particles for Possible Nose-to-Brain Delivery of Ropinirole Hydrochloride: In Vitro and Ex Vivo Evaluation
  17. Nose-to-Heart Approach: Unveiling an Alternative Route of Acute Treatment
  18. Cyclodextrins-block copolymer drug delivery systems: From design and development to preclinical studies
  19. The Complementary Effects of Dabigatran Etexilate and Exercise Training on the Development and Stability of the Atherosclerotic Lesions in Diabetic ApoE Knockout Mice
  20. Comparative Serum and Brain Pharmacokinetics of Quercetin after Oral and Nasal Administration to Rats as Lyophilized Complexes with β-Cyclodextrin Derivatives and Their Blends with Mannitol/Lecithin Microparticles
  21. Recent Advances in Nanoformulations for Quercetin Delivery
  22. Nose-to-Brain delivery of donepezil hydrochloride following administration of an HPMC-Me-β-CD-PEG400 nasal film in mice
  23. Donepezil Brain and Blood Pharmacokinetic Modeling after Nasal Film and Oral Solution Administration in Mice
  24. Advances in intranasal vaccine delivery: A promising non-invasive route of immunization
  25. Development of Hybrid DSPC:DOPC:P(OEGMA950-DIPAEMA) Nanostructures: The Random Architecture of Polymeric Guest as a Key Design Parameter
  26. Development of Novel Pharmaceutical Forms of the Marine Bioactive Pigment Echinochrome A Enabling Alternative Routes of Administration
  27. Bio-Actives from Natural Products with Potential Cardioprotective Properties: Isolation, Identification, and Pharmacological Actions of Apigenin, Quercetin, and Silibinin
  28. Development of a Novel Apigenin Dosage form as a Substitute for the Modern Triple Antithrombotic Regimen
  29. Intranasal Administration of a Polymeric Biodegradable Film to C57BL/6 Mice
  30. Effects of the Antioxidant Quercetin in an Experimental Model of Ulcerative Colitis in Mice
  31. Development and Pharmacokinetics of a Novel Acetylsalicylic Acid Dry Powder for Pulmonary Administration
  32. Pharmacokinetic Characteristics of Nebulized Colistimethate Sodium Using Two Different Types of Nebulizers in Critically Ill Patients with Ventilator-Associated Respiratory Infections
  33. Exercise training inhibits atherosclerosis progression and reduces VE-cadherin levels within atherosclerotic plaques in hypercholesterolemic mice
  34. Association of serum levels of osteopontin and osteoprotegerin with adverse outcomes after endovascular revascularisation in peripheral artery disease
  35. Comparative Interaction Studies of Quercetin with 2-Hydroxyl-propyl-β-cyclodextrin and 2,6-Methylated-β-cyclodextrin
  36. Development and In Vitro-Ex Vivo Evaluation of Novel Polymeric Nasal Donepezil Films for Potential Use in Alzheimer’s Disease Using Experimental Design
  37. Potential Pharmaceutical Applications of Quercetin in Cardiovascular Diseases
  38. Design of a Personalized Nasal Device (Matrix-Piston Nasal Device, MPD) for Drug Delivery: a 3D-Printing Application
  39. A Comprehensive Review of the Cardiovascular Protective Properties of Silibinin/Silymarin: A New Kid on the Block
  40. Losartan Interactions with 2-Hydroxypropyl-β-CD
  41. Development of a Population Pharmacokinetic Model of Busulfan in Children and Evaluation of Different Sampling Schedules for Precision Dosing
  42. The Association of Arterial Stiffness With Significant Carotid Atherosclerosis and Carotid Plaque Vulnerability
  43. Pro‐inflammatory cytokines/chemokines, TNF‐α, IL‐6 and MCP‐1, as biomarkers for the nephro‐ and pneumoprotective effect of silibinin after hepatic ischemia/reperfusion: Confirmation by immunohistochemistry and qRT‐PCR
  44. Nasal powders of quercetin-β-cyclodextrin derivatives complexes with mannitol/lecithin microparticles for Nose-to-Brain delivery: In vitro and ex vivo evaluation
  45. The cardiovascular‐protective properties of saffron and its potential pharmaceutical applications: A critical appraisal of the literature
  46. Flurbiprofen sodium microparticles and soft pellets for nose-to-brain delivery: Serum and brain levels in rats after nasal insufflation
  47. Dose individualization of intravenous busulfan in pediatric patients undergoing bone marrow transplantation: impact and in vitro evaluation of infusion lag-time
  48. The hepatoprotective effect of silibinin after hepatic ischemia/reperfusion in a rat model is confirmed by immunohistochemistry and qRT-PCR
  49. Omentin-1 and vaspin serum levels in patients with pre-clinical carotid atherosclerosis and the effect of statin therapy on them
  50. Effect of silibinin on the expression of MMP2, MMP3, MMP9 and TIMP2 in kidney and lung after hepatic ischemia/reperfusion injury in an experimental rat model
  51. Nonalcoholic fatty liver disease: The role of quercetin and its therapeutic implications
  52. Use of natural anti-oxidants in experimental animal models of hepatic ischemia-reperfusion injury
  53. Silibinin-hydroxypropyl-β-cyclodextrin (SLB-HP-β-CD) complex prevents apoptosis in liver and kidney after hepatic ischemia-reperfusion injury
  54. Application of Neutralization and Technique for the Preparation of the Beneficial in Drug 2-Hydroxypropyl-β-Cyclodextrin with
  55. Preparation and Biophysical Characterization of Quercetin Inclusion Complexes with β-Cyclodextrin Derivatives to be Formulated as Possible Nose-to-Brain Quercetin Delivery Systems
  56. Population pharmacokinetics of micafungin over repeated doses in critically ill patients: a need for a loading dose?
  57. Population pharmacokinetics of anidulafungin in ICU patients assessing inter‐ and intrasubject variability
  58. Comparative pharmacokinetics of the three echinocandins in ICU patients
  59. Antihypertensive activity and molecular interactions of irbesartan in complex with 2‐hydroxypropyl‐β‐cyclodextrin
  60. Hyperhydration using different hydration agents does not affect the haematological markers of the athlete biological passport in euhydrated volunteers
  61. Charting the structural and thermodynamic determinants in phenolic acid natural product – cyclodextrin encapsulations
  62. Glycoprotein non-metastatic melanoma B expression after hepatic ischemia reperfusion and the effect of silibinin
  63. Effect of hyperhydration on the pharmacokinetics and detection of orally administered budesonide in doping control analysis
  64. Hyperhydration Effect on Pharmacokinetic Parameters and Detection Sensitivity of Recombinant Human Erythropoietin in Urine and Serum Doping Control Analysis of Males
  65. Statins’ Withdrawal Induces Atherosclerotic Plaque Destabilization in Animal Model—A “Rebound” Stimulation of Inflammation
  66. Hyperhydration-Induced Decrease in Urinary Luteinizing Hormone Concentrations of Male Athletes in Doping Control Analysis
  67. Host–Guest Interactions between Candesartan and Its Prodrug Candesartan Cilexetil in Complex with 2-Hydroxypropyl-β-cyclodextrin: On the Biological Potency for Angiotensin II Antagonism
  68. Anti-inflammatory flurbiprofen nasal powders for nose-to-brain delivery in Alzheimer’s disease
  69. Preparation, chemical characterization and determination of crocetin's pharmacokinetics after oral and intravenous administration of saffron (Crocus sativusL.) aqueous extract to C57/BL6J mice
  70. Exploring the oxidation and iron binding profile of a cyclodextrin encapsulated quercetin complex unveiled a controlled complex dissociation through a chemical stimulus
  71. The effect of athletes` hyperhydration on the urinary ‘steroid profile’ markers in doping control analysis
  72. Crocus sativus L. aqueous extract reduces atherogenesis, increases atherosclerotic plaque stability and improves glucose control in diabetic atherosclerotic animals
  73. Saffron ( Crocus sativus ) intake provides nutritional preconditioning against myocardial ischemia–reperfusion injury in Wild Type and ApoE (−/−) mice: Involvement of Nrf2 activation
  74. Silibinin Effect on Fas/FasL, HMGB1, and CD45 Expressions in a Rat Model Subjected to Liver Ischemia-Reperfusion Injury
  75. Exploring the interactions of irbesartan and irbesartan–2-hydroxypropyl-β-cyclodextrin complex with model membranes
  76. Silibinin Improves TNF-α and M30 Expression and Histological Parameters in Rat Kidneys After Hepatic Ischemia/Reperfusion
  77. Mapping the interactions and bioactivity of quercetin⿿(2-hydroxypropyl)-β-cyclodextrin complex
  78. Mother's breast milk supplemented with donor milk reduces hospital and health service usage costs in low-birthweight infants
  79. The impact of maternal- and neonatal-associated factors on human milk's macronutrients and energy
  80. Drug Utilization Patterns and Costs of Erythropoiesis-Stimulating Agents in an Outpatient Setting in Greece
  81. Human Milk Banking: a bridge between the preterm mother and infant; the experience from a Greek Public Perinatal Center
  82. Bioassay for Determining Voriconazole Serum Levels in Patients Receiving Combination Therapy with Echinocandins
  83. Serum and tissue pharmacokinetics of silibinin after per os and i.v. administration to mice as a HP-β-CD lyophilized product
  84. Saffron: a natural product with potential pharmaceutical applications
  85. Improved outcomes of feeding low birth weight infants with predominantly raw human milk versus donor banked milk and formula
  86. Investigation of the Interactions of Silibinin with 2-Hydroxypropyl-β-cyclodextrin through Biophysical Techniques and Computational Methods
  87. Gas chromatographic–mass spectrometric quantitation of busulfan in human plasma for therapeutic drug monitoring: A new on-line derivatization procedure for the conversion of busulfan to 1,4-diiodobutane
  88. Keeping a Critical Eye on the Science and the Regulation of Oral Drug Absorption: A Review
  89. Elucidating the Role of Dose in the Biopharmaceutics Classification of Drugs: The Concepts of Critical Dose, Effective In Vivo Solubility, and Dose-Dependent BCS
  90. Pharmacokinetics of doripenem in CSF of patients with non-inflamed meninges
  91. Penetration of Intact Blood-Brain Barrier by Doripenem
  92. Robust and Sensitive High-Performance Liquid Chromatographic-UV Detection Technique for the Determination of Tigecycline in Rabbit Plasma
  93. Computational-Regulatory Developments in the Prediction of Oral Drug Absorption
  94. Supersaturated dissolution data and their interpretation: the TPGS-carbamazepine model case
  95. Biopharmaceutical Classification Based on Solubility and Dissolution: A Reappraisal of Criteria for Hypothesis Models in the Light of the Experimental Observations
  96. Effect of Cyclodextrin Complexation on the Aqueous Solubility and Solubility/Dose Ratio of Praziquantel
  97. Effect of pH and water-soluble polymers on the aqueous solubility of nimesulide in the absence and presence of β-cyclodextrin derivatives
  98. Biopharmaceutics classification systems for new molecular entities (BCS-NMEs) and marketed drugs (BCS-MD): Theoretical basis and practical examples
  99. Development of a reaction-limited model of dissolution: Application to official dissolution tests experiments
  100. Modelling and simulation in drug absorption processes
  101. In-vitro study on the competitive binding of diflunisal and uraemic toxins to serum albumin and human plasma using a potentiometric ion-probe technique
  102. Plasma profiles of lycopene after single oral and intravenous administrations in dogs
  103. Solubilization and quantification of lycopene in aqueous media in the form of cyclodextrin binary systems
  104. Identification of Biowaivers Among Class II Drugs: Theoretical Justification and Practical Examples
  105. Quantitative Biopharmaceutics Classification System: The Central Role of Dose/Solubility Ratio
  106. The power law can describe the ‘entire’ drug release curve from HPMC-based matrix tablets: a hypothesis
  107. Non-linear regression analysis with errors in both variables: estimation of co-operative binding parameters
  108. A displacement approach for competitive drug–protein binding studies using the potentiometric 1-anilino-8-naphthalene-sulfonate probe technique
  109. Modeling of supersaturated dissolution data
  110. Studies on the interaction of diflunisal ion with cyclodextrins using ion-selective electrode potentiometry
  111. Determination of fractal reaction dimension in dissolution studies
  112. General Treatment of Competitive Binding as Applied to the Potentiometric Ion Probe Technique: Application to the Interaction of Nonsteroidal Anti- Inflammatory Drugs with Bovine Serum Albumin
  113. Automated flow-injection technique for use in dissolution studies of sustained-release formulations: Application to iron(II) formulations
  114. Use of 1-Anilino-8-napthalenesulphonate as an Ion Probe for the Potentiometric Study of the Binding of Sulphonamides to Bovine Serum Albumin and Plasma
  115. Binding Studies of Ions with Cyclodextrins Using Ion-Selective Electrodes
  116. Construction of a naproxen ion-selective electrode and its application to pharmaceutical analysis